Literature DB >> 18097032

Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals.

Sebastian Kreiter1, Abderraouf Selmi, Mustafa Diken, Martin Sebastian, Phillip Osterloh, Hansjörg Schild, Christoph Huber, Ozlem Türeci, Ugur Sahin.   

Abstract

Genetic modification of vaccines by linking the Ag to lysosomal or endosomal targeting signals has been used to route Ags into MHC class II processing compartments for improvement of CD4+ T cell responses. We report in this study that combining an N-terminal leader peptide with an MHC class I trafficking signal (MITD) attached to the C terminus of the Ag strongly improves the presentation of MHC class I and class II epitopes in human and murine dendritic cells (DCs). Such chimeric fusion proteins display a maturation state-dependent subcellular distribution pattern in immature and mature DCs, mimicking the dynamic trafficking properties of MHC molecules. T cell response analysis in vitro and in mice immunized with DCs transfected with Ag-encoding RNA showed that MITD fusion proteins have a profoundly higher stimulatory capacity than wild-type controls. This results in efficient expansion of Ag-specific CD8+ and CD4+ T cells and improved effector functions. We used CMVpp65 and NY-ESO-1 Ags to study preformed immune responses in CMV-seropositive individuals and cancer patients. We show that linking these Ags to the MITD trafficking signal allows simultaneous, polyepitopic expansion of CD8+ and CD4+ T cells, resulting in distinct CD8+ T cell specificities and a surprisingly broad and variable Ag-specific CD4+ repertoire in different individuals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18097032     DOI: 10.4049/jimmunol.180.1.309

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling.

Authors:  Hongxia Zhang; Xinru You; Xiaojuan Wang; Lei Cui; Zining Wang; Feifei Xu; Mengyun Li; Zhenggang Yang; Jinyun Liu; Peng Huang; Yang Kang; Jun Wu; Xiaojun Xia
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

2.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

3.  Structurally Programmed Assembly of Translation Initiation Nanoplex for Superior mRNA Delivery.

Authors:  Jiahe Li; Wade Wang; Yanpu He; Yingzhong Li; Emily Z Yan; Ketian Zhang; Darrell J Irvine; Paula T Hammond
Journal:  ACS Nano       Date:  2017-02-14       Impact factor: 15.881

Review 4.  DNA vaccines for targeting bacterial infections.

Authors:  Mariana Ingolotti; Omkar Kawalekar; Devon J Shedlock; Karuppiah Muthumani; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

Review 5.  Developing mRNA-vaccine technologies.

Authors:  Thomas Schlake; Andreas Thess; Mariola Fotin-Mleczek; Karl-Josef Kallen
Journal:  RNA Biol       Date:  2012-10-12       Impact factor: 4.652

6.  Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.

Authors:  An M T Van Nuffel; Daphné Benteyn; Sofie Wilgenhof; Lauranne Pierret; Jurgen Corthals; Carlo Heirman; Pierre van der Bruggen; Pierre G Coulie; Bart Neyns; Kris Thielemans; Aude Bonehill
Journal:  Mol Ther       Date:  2012-02-28       Impact factor: 11.454

Review 7.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

Review 8.  A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Authors:  Karl-Josef Kallen; Andreas Theß
Journal:  Ther Adv Vaccines       Date:  2014-01

Review 9.  The use of signal peptide domains as vaccine candidates.

Authors:  Riva Kovjazin; Lior Carmon
Journal:  Hum Vaccin Immunother       Date:  2014-10-30       Impact factor: 3.452

Review 10.  Dendritic cell-based human immunodeficiency virus vaccine.

Authors:  C R Rinaldo
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.